Johnson & Johnson said Wednesday that new data from early trials of a booster shot of its COVID-19 vaccine provides a "rapid and robust increase in spike-binding antibodies" that fight off the virus.
Video above: FDA votes to authorize more COVID-19 boosters, mix-and-matching doses in some casesA booster dose of the Pfizer/BioNTech coronavirus vaccine was found to have a high efficacy — 95.6% — ...
Vaxxinity’s next-generation COVID-19 booster candidate UB-612 achieves primary and key secondary immunogenicity endpoints in a pivotal head-to-head heterologous booster trial against three authorized ...
ATLANTA, GA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire-- GeoVax Labs, Inc. (GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, ...
Pfizer and BioNTech on Thursday said a booster shot of their COVID-19 vaccine was 95.6% effective in preventing infection from the virus compared to those who did not receive a third dose. In a press ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results